Alimera Sciences Inc (NASDAQ:ALIM) has earned a consensus recommendation of “Buy” from the six analysts that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $3.00.

A number of analysts have weighed in on ALIM shares. Craig Hallum started coverage on shares of Alimera Sciences in a research note on Tuesday, May 28th. They set a “buy” rating and a $3.00 target price on the stock. ValuEngine raised shares of Alimera Sciences from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. HC Wainwright reaffirmed a “buy” rating on shares of Alimera Sciences in a research note on Friday, June 21st. Finally, Zacks Investment Research raised shares of Alimera Sciences from a “sell” rating to a “hold” rating in a research note on Thursday.

NASDAQ:ALIM traded down $0.01 during mid-day trading on Friday, reaching $0.50. The stock had a trading volume of 322,400 shares, compared to its average volume of 313,397. The stock has a 50-day simple moving average of $0.77 and a two-hundred day simple moving average of $0.94. Alimera Sciences has a 12 month low of $0.46 and a 12 month high of $1.21.

Alimera Sciences (NASDAQ:ALIM) last posted its earnings results on Monday, July 29th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.03). The business had revenue of $10.86 million for the quarter, compared to analysts’ expectations of $12.97 million. As a group, analysts anticipate that Alimera Sciences will post -0.16 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC grew its stake in shares of Alimera Sciences by 13.1% during the second quarter. Renaissance Technologies LLC now owns 1,128,404 shares of the biopharmaceutical company’s stock worth $1,004,000 after buying an additional 130,414 shares during the last quarter. Royce & Associates LP grew its stake in shares of Alimera Sciences by 79.0% during the first quarter. Royce & Associates LP now owns 571,275 shares of the biopharmaceutical company’s stock worth $606,000 after buying an additional 252,089 shares during the last quarter. Knott David M lifted its holdings in shares of Alimera Sciences by 3.9% during the first quarter. Knott David M now owns 402,901 shares of the biopharmaceutical company’s stock worth $427,000 after purchasing an additional 15,000 shares during the period. B. Riley Wealth Management Inc. lifted its holdings in shares of Alimera Sciences by 36.7% during the first quarter. B. Riley Wealth Management Inc. now owns 139,302 shares of the biopharmaceutical company’s stock worth $148,000 after purchasing an additional 37,396 shares during the period. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of Alimera Sciences by 32,745.5% during the second quarter. Tower Research Capital LLC TRC now owns 54,852 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 54,685 shares during the period. 50.71% of the stock is currently owned by hedge funds and other institutional investors.

Alimera Sciences Company Profile

Alimera Sciences, Inc, a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness.

Featured Article: How accurate is the Rule of 72?

Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.